Drugs / CD4+CD25+ regulatory T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00725062 | Jun 2008 → Apr 2010 | graft versus host disease, leukemia, myelodysplastic syndrome, plasma cell neoplasm | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD4+CD25+ regulatory T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00725062 ↗ |
| Route | Intravenous | “CD4+/CD25+ cells given intravenously over 15-60 minutes on Day -2” NCT00725062 ↗ |